HomeCompareEKDHF vs GBDC

EKDHF vs GBDC: Dividend Comparison 2026

EKDHF yields 588.53% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.34M in total portfolio value· pulled ahead in Year 8
10 years
EKDHF
EKDHF
● Live price
588.53%
Share price
$0.34
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$436.3K
Annual income
$1,271.11
Full EKDHF calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — EKDHF vs GBDC

📍 GBDC pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEKDHFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EKDHF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EKDHF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EKDHF
Annual income on $10K today (after 15% tax)
$50,025.01/yr
After 10yr DRIP, annual income (after tax)
$1,080.44/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,929,793.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EKDHF + GBDC for your $10,000?

EKDHF: 50%GBDC: 50%
100% GBDC50/50100% EKDHF
Portfolio after 10yr
$10.61M
Annual income
$8,195,267.25/yr
Blended yield
77.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

EKDHF
No analyst data
Altman Z
9.2
Piotroski
7/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EKDHF buys
0
GBDC buys
2
PoliticianChamberTickerTypeAmountDate
David P. Joyce🏢 House$GBDC▼ Sell$1,001 - $15,0002023-06-30
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002023-06-19
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-14
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-12
Teresa Leger Fernandez🏢 House$GBDC▼ Sell$15,001 - $50,0002021-01-20
David P. Joyce🏢 House$GBDC▲ Buy$1,001 - $15,0002020-02-25
David P. Joyce🏢 House$GBDC▲ Buy$15,001 - $50,0002019-05-30
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEKDHFGBDC
Forward yield588.53%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%51.1%
Portfolio after 10y$436.3K$20.78M
Annual income after 10y$1,271.11$16,389,263.41
Total dividends collected$267.1K$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: EKDHF vs GBDC ($10,000, DRIP)

YearEKDHF PortfolioEKDHF Income/yrGBDC PortfolioGBDC Income/yrGap
1$40,126$29,426.48$12,490$1,790.28+$27.6KEKDHF
2$98,112$55,176.68$16,522$3,157.73+$81.6KEKDHF
3$168,022$63,042.42$23,578$5,898.68+$144.4KEKDHF
4$230,234$50,450.31$37,115$11,886.75+$193.1KEKDHF
5$278,654$32,303.75$66,136$26,423.57+$212.5KEKDHF
6$316,430$18,269.86$137,257$66,491.44+$179.2KEKDHF
7$348,275$9,694.67$341,734$194,868.54+$6.5KEKDHF
8← crossover$377,640$4,986.13$1,050,788$685,133.02$673.1KGBDC
9$406,601$2,526.42$4,099,314$2,974,971.01$3.69MGBDC
10$436,334$1,271.11$20,775,530$16,389,263.41$20.34MGBDC

EKDHF vs GBDC: Complete Analysis 2026

EKDHFStock

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

Full EKDHF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this EKDHF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EKDHF vs SCHDEKDHF vs JEPIEKDHF vs OEKDHF vs KOEKDHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.